Results Dose-Escalating Study With the Fetal Estrogen Estetrol in Healthy Men published in The Journal of Clinical Endocrinology & Metabolism

Luteinizing hormone–releasing hormone agonists have replaced estrogens for endocrine treatment of advanced prostate cancer (PC) because of cardiovascular side effects. The published study with the fetal estrogen estetrol (E4) in healthy males shows promise as a safe and effective drug for use in prostate cancer.

A Dose-Escalating Study With the Fetal Estrogen JCEM 2018


Pantarhei Bioscience BV | Boulevard 17 | 3707 BK Zeist | The Netherlands
Phone: +31 (0)30 6 985 020 | Email:


The information contained in this website is for general information purposes only. The information is provided by Pantarhei Bioscience and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.